Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 214 participants.
Also called NCT03604419
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 214 participants
- Sponsor
- Registry
-
NCT03604419
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03604419. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-13 (actual); primary completion 2019-07-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- PB-119 100 μg+ Glucophage®
- Intervention (Drug)
- PB-119 150 μg+ Glucophage®
- Intervention (Drug)
- PB-119 200 μg+ Glucophage®
- Intervention (Drug)
- PB-119 placebo + Glucophage®
- Lead sponsor
- PegBio Co., Ltd.
- Collaborator
- Covance
Record details
- Record id
cardio:ct-nct03604419- Content hash
bd1bdaf1236cf77b089be465d4d869593c2bf92f0a3ae3d72d04d96eec469e99